DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus

2013 ◽  
Vol 59 (5) ◽  
pp. 72-80
Author(s):  
Iu Sh Khalimov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adverse Events ◽  
Clinical Condition ◽  
Hypoglycemic Agents ◽  
The Novel ◽  
Oral Hypoglycemic Agents ◽  
Novel Approaches

The incidence of hypoglycemia remains rather high among the population of patients with type 2 diabetes mellitus (DM2) especially in those treated with the traditional oral hypoglycemic agents. Hypoglycemia is one of the most frequent adverse events encountered by a physician dealing with diabetic (DM2) patients. At the same time, the novel approaches are currently available that allow this clinical condition to be avoided.

scholarly journals Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients

2016 ◽  
Vol 10 (1) ◽  
pp. 36 ◽  
Author(s):  
Antonio Asti ◽  
Alessandra D'Alessandro ◽  
Francesco Paolo Zito ◽  
Salvatore Nardi ◽  
Giovanni Sarnelli ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adverse Events ◽  
Total Cholesterol ◽  
Statistical Significance ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents

Sitagliptin and saxagliptin are oral hypoglycemic agents inhibitors of DPP-4, indicated in the treatment of type 2 diabetes mellitus in combination with metformin, in patients who have not achieved adequate glycemic control. In our study we enrolled 128 decompensated type 2 diabetes patients while on metformin maximum dosage. At time 0’ we have detected, body mass index (BMI), total cholesterol, high- and low-density lipoproteins (HDL and LDL), triglycerides, transaminases and pancreatic amylase; patients were randomized to receive sitagliptin or saxagliptin; follow-up was performed after 4 months with the revaluation of the same variables and adverse events. In both sitagliptin and saxagliptin groups we observed a significant reduction in fasting glucose, glycated hemoglobin, weighing, BMI, triglycerides, while the reduction in total cholesterol, LDL cholesterol did not reach statistical significance. There was no suspension of therapy, adverse events appeared minor and temporary. In conclusion, our observations highlight the almost identical efficacy of sitagliptin and saxagliptin. These data reinforce even more the idea that we should think about this class of drugs as the next step in patients failing therapy with metformin.

scholarly journals The importance and advantages of the timely prescription of insulin to the patients with type 2 diabetes mellitus

2012 ◽  
Vol 58 (3) ◽  
pp. 56-60
Author(s):  
I R Iarek-Martynova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Clinical Situation ◽  
Hypoglycemic Agents ◽  
Negative Consequences ◽  
Oral Hypoglycemic Agents ◽  
Adequate Treatment

The onset of insulin therapy is an important stage in the treatment of type 2 diabetes mellitus. Its timely beginning ensures better control of glycemia and reduces the negative consequences of chronic glucose cytotoxicity and lipotoxicity. The achievement and maintenance of the stable compensation of the disease are the indispensable conditions for successful prophylaxis and adequate treatment of chronic complications of diabetes mellitus. The ADA guidelines recommend to initiate insulin therapy at the early stages of the disease provided it is dictated by the clinical situation or combine it with the use of oral hypoglycemic agents if the targeted HbA1c levels fail to be reached despite the intake of one or more tableted preparations.

scholarly journals Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus

2017 ◽  
Vol 41 (5) ◽  
pp. 357 ◽  
Author(s):  
Min Kyong Moon ◽  
Kyu-Yeon Hur ◽  
Seung-Hyun Ko ◽  
Seok-O Park ◽  
Byung-Wan Lee ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents

Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus

2016 ◽  
Vol 63 (10) ◽  
pp. 519-526
Author(s):  
Irene Romera ◽  
Francisco Javier Ampudia-Blasco ◽  
Antonio Pérez ◽  
Bernat Ariño ◽  
Egon Pfarr ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hypoglycemic Agents ◽  
Efficacy And Safety ◽  
Oral Hypoglycemic Agents

scholarly journals Glycemic Control of Type 2 Diabetic Patients Managed in Tertiary Care Internal Medicine Clinics Using HbA1c

2013 ◽  
Vol 3 (1) ◽  
pp. 23-28
Author(s):  
Helal S. Alenezi ◽  
Mubasher Kharal ◽  
Muhammad Yousuf ◽  
Yousef Al Saleh ◽  
Salih Bin Salih
Keyword(s):  
Internal Medicine ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
American Diabetes Association ◽  
Diabetic Control ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents

Background /Objective: The aim was to assess the glycemic control in patients with type 2 diabetes mellitus using American Diabetes Association HbA1c definition of good control of ≤ 7.0%. Methods: This retrospective study conducted in internal medicine outpatient clinics at King Abdulaziz Medical City in Riyadh, Kingdom of Saudi Arabia. All patients with type 2 diabetes mellitus attending the clinic from August 2005 to January 2006 were evaluated. Patients with HbA1c measured regularly and under anti-diabetic therapy were included in the study. Last measured HbA1c was used to evaluate diabetic control. Results: Data for 968 (81.5%) patients out of 1188 were available for analysis. Only 211 (21.8%) patients had their HbA1c within the American Diabetes Association recommended target of HbA1c ≤ 7%. Mean HbA1c was 8.98%. Patients were stratified into groups of good (HbA1c £ 7%), average (HbA1c 7.1% - 9.9%) and poor diabetic control (HbA1c ≥ 10%) included 21.8%, 46.2% and 32.0% of the study population, respectively. Mean HbA1c in patients on diabetic diet only, oral hypoglycemic agents, insulin, and oral hypoglycemic agents plus insulin was 7.62%, 8.67%, 8.92% and 9.70%, respectively. Conclusion: Majority of patients in our study did not meet the American Diabetes Association recommended target HbA1c for type 2 diabetes mellitus. Causes for this failure need to be assessed in Saudi type 2 diabetes mellitus population.

Sign in / Sign up

Export Citation Format

Share Document